Finally, the analyses of PTEN and RB1 captured most of the differential CNA-IC50 associations, and the corresponding drug targets (i.e. the targets of the analyzed drug IC50) were frequently found to be differentially expressed in cancer cell lines harboring PTEN or RB1 mutations (empirical p values < 0.05; Fig. 4d). Here, RB1 is linked to cancer.